Quarterly ResultMay 6, 2026, 07:12 AM
Madrigal Q1 Rezdiffra Net Sales $311.3M, up 127%; Adds siRNA Asset
AI Summary
Madrigal Pharmaceuticals reported strong first-quarter 2026 financial results, with Rezdiffra net sales reaching $311.3 million, a 127% increase year-over-year. The company also announced a global licensing agreement for a clinical-stage siRNA asset targeting a PNPLA3 gene mutation, expanding its MASH pipeline. As of March 31, 2026, over 42,250 patients were on Rezdiffra, reflecting continued strong demand. Despite increased operating expenses due to commercial investments and business development, the company maintains a strong cash position of $817.9 million.
Key Highlights
- Rezdiffra net sales were $311.3 million in Q1 2026, a 127% year-over-year increase.
- Over 42,250 patients were on Rezdiffra as of March 31, 2026, up 2.5x from Q1 2025.
- Operating expenses for Q1 2026 were $404.1 million, including $54.3 million in one-time business development expenses.
- Net loss for Q1 2026 was $94.4 million, or $3.25 per share.
- Cash, cash equivalents, restricted cash, and marketable securities totaled $817.9 million as of March 31, 2026.
- R&D expenses increased to $108.7 million in Q1 2026, primarily due to $54.3 million in business development expenses.
- SG&A expenses rose to $268.5 million in Q1 2026, driven by Rezdiffra commercial activities.
Price Impact
More from MDGL